Breaking Finance News

Swiss Re (ETR:SR9) stock price target increased to 100.00EUR, issued a report today by Macquarie Research

In a statement issued on 11/23/2016 Macquarie Research upped the target of Swiss Re (ETR:SR9) to 100.00EUR stating a potential upside of 0.07%.

Previously on 11/22/2016, Macquarie Research reported about Swiss Re (ETR:SR9) upped the target price from 0.00EUR to 100.00EUR that indicated a possible upside of 0.07%.

Only yesterday Swiss Re (ETR:SR9) traded 0.00% even at 93.35EUR. Swiss Re’s 50-day average is 0.00EUR and its two hundred day average is 0.00EUR. With the last stock price close up 0.00% relative to the two hundred day average, compared with the S&P 500 which has decreased -0.03% over the same time period. 0 shares of the stock were exchanged, down from an average trading volume of 0

Performance Chart

Swiss Re (ETR:SR9)

With a total market value of 0 EUR, Swiss Re has 52 week low of 0.00EUR and a 52 week high of 0.00EUR .

Brief Synopsis About Swiss Re (ETR:SR9)

Swiss Re AG is a wholesale provider of reinsurance, insurance and other insurance-based forms of risk transfer. The Company's clients include insurance companies, mid- to large-sized corporations and public sector clients. Its segments include Property&Casualty Reinsurance, Life&Health Reinsurance, Corporate Solutions and Admin Re. Its Reinsurance Unit provides premiums and fee income through Property&Casualty and Life&Health segments. The Corporate Solutions segment is engaged in serving mid-sized and large corporations, with product offerings ranging from traditional property and casualty insurance to customized solutions. The Admin Re segment provides risk and capital management solutions by which the Company acquires closed books of in-force life and health insurance business, entire lines of business, or the entire capital stock of life insurance companies. The Company's open and closed life insurance books, including Admin Re, are managed under a unit called Life Capital.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *